Avista Public Acquisition Corp. II
Completed
Follow
Detailed Information
Information on this SPAC.
- Sponsors
- IPO Size
- $200M
- Underwriters
- Focus
- Healthcare
- SEC Filings
- 1846253
- Public Embarc Page
- https://embarc.com/capital/spac/1846253/AHPA/avista-public-acquisition
- IPO Ticker
- AHPA
SPAC Leadership
Information on the SPAC leadership.
- Executive Chairman and DirectorThompson Dean(Managing Partner & Co-CEO of Avista)
- President, Chief Executive Officer and DirectorDavid Burgstahler
- Executive Vice PresidentSriram Venkataraman
- Executive Vice PresidentRobert Girardi
- Investor Relations OfficerAmanda Heravi
- Chief Financial OfficerJohn Cafasso
- General CounselBenjamin Silbert
- DirectorWilliam E. Klitgaard
- DirectorLâle White
- DirectorWendel Barr
Target Information
Information on the SPAC target for merger.
- Company
- OmniAb
- Presentation
- Investor Presentation (SEC) on 2022-03-23
- Description
- Ligand’s OmniAb antibody discovery platform "provides pharmaceutical industry partners with access to diverse antibody repertoires and high-throughput screening technologies to enable discovery of next-generation therapeutics."